Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 56 of the 84 sources its claims cite were checked for support.
Abstract
animal studies fail to fully recapitulate human cardiac physiology, highlighting the urgent need for more relevant human-based models. Engineered three-dimensional cardiac systems - including organoids, engineered heart tissues, and heart-on-chip platforms offer promising alternatives, providing structural and functional insights into cardiac biology. However, a critical limitation of these models is their inability to perform fluid pumping and relaxation, which together define fundamental heart function. Engineered cardiac chambers have emerged to address this gap, enabling physiologically relevant pressure-volume measurements and capturing both contractile and diastolic dynamics that mimic aspects of native cardiac hemodynamics. This mini-review examines the current state of engineered cardiac chambers and highlights their main design features. We discuss their applications in disease modeling and drug testing, and outline key factors influencing the optimization of these models, including balancing biological fidelity with process efficiency through modular design principles. Overall, engineered cardiac chambers represent a unique, powerful platform to improve mechanistic understanding of cardiac disease, offering significant potential to advance cardiovascular research and therapeutic development.
Overview
CoChat Summary
## TL;DR
This mini-review argues that engineered cardiac chambers (“mini-hearts”) are the most physiologically relevant 3D cardiac in vitro platforms because they can pump fluid and support pressure-volume (PV) readouts, making them especially useful for disease modeling and drug testing. It emphasizes that future progress depends on balancing biological functionality with process optimization, often through modular design.
## Key findings
- Engineered cardiac chambers (ECCs) address a key limitation of other 3D cardiac models: they can perform fluid pumping and enable PV measurements, including contractile and diastolic dynamics.
- The review identifies several design features that improve physiological relevance, including perfusion, valve integration, cardiomyocyte alignment, complex geometries, and functional readouts; however, perfusion is described as “critical and underrepresented.”
- Existing ECCs have already shown drug responses to cardioactive compounds such as isoproterenol, nifedipine, vasopressin, carbachol, and phenylephrine, and have been used to model myocardial infarction, Friedreich’s ataxia, HFpEF, and structural arrhythmia.
- The paper reports that the miniaturized ECC approach by Michas et al. is the most cell-efficient, using about 174,000 cells per ECC, while existing models span from about 174,000 to about 15 million cells per construct; the highest performing model reports an ejection fraction of about 6%, below the physiological range of 50%–70%.
## Methods
- This is a mini-review of existing engineered cardiac chamber platforms, not an original experimental study.
- The review synthesizes previously published ECC models, focusing on fabrication processes, cell types and density, throughput, PV readouts, and applications in disease modeling and drug testing.
- The main analysis is a qualitative comparison of design trade-offs between biological functionality and process optimization, with attention to modular design principles and context-of-use.
## Limitations
- The paper states that no existing platform excels equally in all dimensions, and that trade-offs are unavoidable between process efficiency and physiological complexity.
- The text notes that simultaneous PV measurements are currently limited to invasive micro-catheter systems adapted from in vivo mouse experiments, and that these may be inaccurate in cell culture media and incompatible with electrical pacing.
- Evident from the text: this is a narrative mini-review rather than a systematic review, so the selection and weighting of examples appear qualitative rather than based on a formally described search or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
38 Valid · 2 Not valid · 7 Not checked · 20 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Some of these more complex engineered cardiac chambers lack functional readouts, thus, limiting their use for drug testing and disease modeling (Esser et al., 2023; Xie et al., 2023; Lee et al., 2019).”
§ Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality > Existing engineered cardiac chambers > Focus features in existing cardiac chambers
What the sources say
- Supportedcites Esser et al., 2023 source
The Main section describes a printed miniature heart with chambers and major vessels for which no electrical activity or contractility was demonstrated. The Supplementary Video S2 passage says engineered cardiac tissues must show physiological responses to pharmacological stimulation to be suitable as model systems, supporting the stated limitation for drug testing; the Main section also identifies disease modeling as a use for engineered cardiac tissues. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Xie et al., 2023 source
- Disputedcites Lee et al., 2019 sourceExperimental — accuracy not yet measured
The paper’s account of its printed ventricle (Fig. 3; p. 482–487) reports functional readouts, including calcium-wave propagation, pacing response, wall motion, and change in chamber area during contraction. It also reports electrophysiologic behavior associated with arrhythmogenic disease states. Thus, this paper does not support citing its cardiac chamber as one that lacks functional readouts. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These models more closely resemble the structural architecture of the heart, pump fluid, allow for analysis of Pressure-Volume (PV) readouts, facilitate control of preload and afterload, and are exposed to multiaxial stress (Li et al., 2018; MacQueen et al., 2018).”
§ Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality > Introduction
What the sources say
- Not matchedcites Li et al., 2018
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites MacQueen et al., 2018 source
The “Intra-ventricular pressure and volume measurements” section reports measuring pressure and volume in engineered ventricles and plotting PV loops from those measurements (Fig. 3b). This directly supports the attributed claim that these models allow analysis of PV readouts. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These models more closely resemble the structural architecture of the heart, pump fluid, allow for analysis of Pressure-Volume (PV) readouts, facilitate control of preload and afterload, and are exposed to multiaxial stress (Li et al., 2018; MacQueen et al., 2018).”
§ Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality > Introduction
What the sources say
- Not matchedcites Li et al., 2018
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites MacQueen et al., 2018 source
The Introduction contrasts earlier cardiac organoid chambers, whose isotropic hydrogels lack a scaffold to guide native-like laminar tissue formation, with this paper’s 3D scaffolds designed to guide that formation. The Tissue-engineered ventricle chamber section reports fiber-directed cell alignment in the resulting chambers. Together, these passages support the architectural comparison. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A major contributor is the limited predictability of preclinical studies, often reliant on Two-dimensional (2D) in vitro platforms and in vivo animal models.”
§ Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality > Introduction
What the sources say
- Partly supportedcites Marshall et al., 2018 sourceExperimental — accuracy not yet measured
The Introduction says that limited predictive value of preclinical studies contributes to drug-candidate failure, and “Setting the stage” describes toxicities missed by preclinical animal testing. The section on 3D tissues says organ chips address limitations of 2D models, but the cited passages do not establish that preclinical studies often rely on 2D platforms. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These models more closely resemble the structural architecture of the heart, pump fluid, allow for analysis of Pressure-Volume (PV) readouts, facilitate control of preload and afterload, and are exposed to multiaxial stress (Li et al., 2018; MacQueen et al., 2018).”
§ Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality > Introduction
What the sources say
- Not matchedcites Li et al., 2018
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites MacQueen et al., 2018 source
The “Bioreactor for modular assembly of ventricles and valves” section reports intra-ventricular fluid flow and demonstrates assisted pumping by the engineered ventricles. The “Intra-ventricular pressure and volume measurements” section also reports volume changes during contraction. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
27 more claims · 14 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 13
Citations
Cites
3D bioprinting of collagen to rebuild components of the human heart
Lee, A., Hudson, A. R., Shiwarski, D. J., Tashman, J. W., Hinton, T. J., Yerneni, S., Bliley, J. M., Campbell, P. G., & Feinberg, A. W. (2019) · Science · doi:10.1126/science.aav9051 · Cited by 1,782
The Global Burden of Cardiovascular Diseases and Risk Factors
Mensah, G. A., Roth, G. A., & Fuster, V. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.009 · Cited by 1,324 · cited 1×
“In 2017 alone, CVDs accounted for 17.8 million deaths globally, a trend that continues to rise (Mensah et al., 2019).”
InfluentialOrgans-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · cited 2×
“One foundational aspect is the inclusion of appropriate mature cell types (Low et al., 2021; Wnorowski et al., 2019).”
Are animal models predictive for humans?
Shanks, N., Greek, R., & Greek, J. (2009) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-4-2 · Cited by 677 · cited 1×
“In vivo testing, despite providing a comprehensive organism-level response, is hindered by physiological discrepancies between species, ethical concerns, and high costs (Ayuso et al., 2021; Shanks et al., 2009).”
Cardioids reveal self-organizing principles of human cardiogenesis
Hofbauer, P., Jahnel, S. M., Papai, N., Giesshammer, M., Deyett, A., Schmidt, C., Penc, M., Tavernini, K., Grdseloff, N., Meledeth, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.034 · Cited by 588
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
Lewis-Israeli, Y. R., Wasserman, A. H., Gabalski, M. A., Volmert, B. D., Ming, Y., Ball, K. A., Yang, W., Zou, J., Ni, G., Pajares, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25329-5 · Cited by 536
Development of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510 · cited 1×
“…positioned between two flexible micropillars, are ideal for examining cardiac contractile performance based on pillar deflection upon beating (Ronan et al., 2023; Liu et al., 2023; Windt et al., 2023; Ribeiro et al., 2022; Mannhardt et al., 2016; Hansen et al., 2010; Turnbull et al., 2014).”
Human Engineered Heart Tissue: Analysis of Contractile Force
Mannhardt, I., Breckwoldt, K., Letuffe-Brenière, D., Schaaf, S., Schulz, H., Neuber, C., Benzin, A., Werner, T., Eder, A., Schulze, T., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.011 · Cited by 398
Severino, P., D'Amato, A., Pucci, M., Infusino, F., Adamo, F., Birtolo, L. I., Netti, L., Montefusco, G., Chimenti, C., Lavalle, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218118 · Cited by 349
Metadata
- Authors
- Hecking, J., Cano-Jorge, M., Passier, R., & Rivera-Arbeláez, J. M.
- Affiliations
- University of Twente (NL)
- Leiden University Medical Center (NL)
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2026-01-05
- Volume
- 13
- Pages
- 1719533-1719533
- ISSN
- 2296-4185 (ISSN-L)
- PMC
- PMC12813005
- OpenAlex
- W7118192090
- Semantic Scholar
- 3d06ae8e9bb19723f5bbe0a79562367281456249
- Cited by
- 0
- References
- 60
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- University of Twente Research Information (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Research Council (101098372)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024003001)
- Horizon Europe European Innovation Council (101070953)
- Topics
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Mechanical Circulatory Support Devices
- Keywords
- disease modeling, drug testing, cardiac organoids, engineered heart tissue, cardiac contractility, diastolic function, cardiac hemodynamics, modular design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality. https://app.cochat.ai/papers/10.3389/fbioe.2025.1719533
- The paper
- Hecking, J., Cano-Jorge, M., Passier, R., & Rivera-Arbeláez, J. M. (2026). Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1719533
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.